Further research on nasal iotacarrageenan is warranted. Further research on nasal iota-carrageenan is warranted. The increase in recovery rate was 139 for coronavirus infections, 119 for influenza A infections. ![]() Given that carrageenan has an effect on diverse virus groups, and effects at the clinical level on two old coronaviruses, it seems plausible that carrageenan may have an effect on COVID-19. 003) reduction in the risk of longer colds. In the placebo group, 21 patients had colds lasting over 20 days, compared with six patients in the carrageenan group, which corresponds to a 71% (p =. ![]() Carrageenan had no meaningful effect on shorter colds. The 13.7-day colds were shortened by 3.8 days (28% reduction), and 8.8-day colds by 1.3 days (15% reduction). The fifth quintile contained patients with censored data. Typically, people can become ill with COVID-19 after the SARS-CoV-2 virus has entered the body through the nose or throat. The mean duration of all colds in the placebo groups of the first four quintiles were 4.0, 6.8, 8.8, and 13.7 days, respectively. The increase in recovery rate was 139% for coronavirus infections, 119% for influenza A infections, and 70% for rhinovirus infections. Nasal carrageenan increased the recovery rate from all colds by 54% (95% CI 15%-105% p =. We also used quantile regression to calculate the effect of carrageenan on colds of differing lengths. We used Cox regression to estimate the effect of carrageenan on recovery rate. In both trials, iota-carrageenan was administered nasally three times per day for 7 days for patients with the common cold and follow-up lasted for 21 days. In this individual patient data meta-analysis we examined datasets of two randomized placebo-controlled trials which investigated the effect of nasal carrageenan separately on children and adults. Title:Ĭarrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data Hemilä, H & Chalker, E 2021, ' Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data ', Pharmacology Research & Perspectives, vol.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |